Literature DB >> 21617991

Sclerostin levels during growth in children.

S Kirmani1, S Amin, L K McCready, E J Atkinson, L Joseph Melton, R Müller, S Khosla.   

Abstract

UNLABELLED: Serum sclerostin levels are associated with cortical porosity, suggesting that changes in sclerostin production during growth may play a role in defining cortical structure.
INTRODUCTION: Sclerostin, produced by osteocytes, is a potent inhibitor of Wnt signaling and bone formation. While sclerostin levels increase with age in adults and are higher in men compared to women, there is currently no information on changes in circulating sclerostin levels during growth in humans.
METHODS: We measured serum sclerostin levels in 6- to 21-year-old girls (n = 62) and boys (n = 56) and related these to trabecular and cortical bone microarchitectural parameters using high-resolution peripheral quantitative computed tomography and to markers of bone turnover.
RESULTS: Serum sclerostin levels were higher in boys as compared to girls and declined in both sexes following the onset of puberty. There was no consistent relationship between sclerostin levels and trabecular bone parameters in either sex. However, serum sclerostin levels were inversely associated with cortical volumetric bone mineral density and cortical thickness in girls and positively associated with the cortical porosity index in both girls and boys. Bone turnover markers were positively correlated with serum sclerostin levels in both sexes.
CONCLUSION: The gender difference in serum sclerostin levels appears to be established during puberty, and sclerostin levels tend to decline in late puberty in both girls and boys. Serum sclerostin levels are associated with cortical porosity, suggesting that changes in sclerostin production during growth may play a role in defining cortical structure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617991      PMCID: PMC3606589          DOI: 10.1007/s00198-011-1669-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  30 in total

1.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

Review 2.  SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.

Authors:  Rutger L van Bezooijen; Peter ten Dijke; Socrates E Papapoulos; Clemens W G M Löwik
Journal:  Cytokine Growth Factor Rev       Date:  2005-06       Impact factor: 7.638

3.  SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.

Authors:  Mikhail Semënov; Keiko Tamai; Xi He
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

4.  In vivo high resolution 3D-QCT of the human forearm.

Authors:  A Laib; H J Häuselmann; P Rüegsegger
Journal:  Technol Health Care       Date:  1998-12       Impact factor: 1.285

5.  Ridge number density: a new parameter for in vivo bone structure analysis.

Authors:  A Laib; T Hildebrand; H J Häuselmann; P Rüegsegger
Journal:  Bone       Date:  1997-12       Impact factor: 4.398

6.  Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.

Authors:  Kenneth E S Poole; Rutger L van Bezooijen; Nigel Loveridge; Herman Hamersma; Socrates E Papapoulos; Clemens W Löwik; Jonathan Reeve
Journal:  FASEB J       Date:  2005-08-25       Impact factor: 5.191

Review 7.  Regulation of bone mass by Wnt signaling.

Authors:  Venkatesh Krishnan; Henry U Bryant; Ormond A Macdougald
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  Fracture patterns in children. Analysis of 8,682 fractures with special reference to incidence, etiology and secular changes in a Swedish urban population 1950-1979.

Authors:  L A Landin
Journal:  Acta Orthop Scand Suppl       Date:  1983

9.  Epidemiology of distal forearm fractures in Danish children.

Authors:  M Kramhøft; S Bødtker
Journal:  Acta Orthop Scand       Date:  1988-10

10.  Calibration of trabecular bone structure measurements of in vivo three-dimensional peripheral quantitative computed tomography with 28-microm-resolution microcomputed tomography.

Authors:  A Laib; P Rüegsegger
Journal:  Bone       Date:  1999-01       Impact factor: 4.398

View more
  24 in total

1.  Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls.

Authors:  Alexander T Faje; Pouneh K Fazeli; Debra K Katzman; Karen K Miller; Anne Breggia; Clifford J Rosen; Nara Mendes; Anne Klibanski; Madhusmita Misra
Journal:  Bone       Date:  2012-06-15       Impact factor: 4.398

Review 2.  Monitoring Bone Health in Children with Hemophilic Arthropathy: Where Do We Stand?

Authors:  Alpesh Goyal; Rajesh Khadgawat
Journal:  Indian J Pediatr       Date:  2019-04-10       Impact factor: 1.967

Review 3.  From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.

Authors:  Vincent M Brandenburg; Patrick D'Haese; Annika Deck; Djalila Mekahli; Björn Meijers; Ellen Neven; Pieter Evenepoel
Journal:  Pediatr Nephrol       Date:  2015-03-04       Impact factor: 3.714

Review 4.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

5.  Serum sclerostin levels in healthy men over 50 years of age.

Authors:  Harjit Pal Bhattoa; John Wamwaki; Edit Kalina; Roza Foldesi; Adam Balogh; Peter Antal-Szalmas
Journal:  J Bone Miner Metab       Date:  2013-03-24       Impact factor: 2.626

Review 6.  Clinical utility of serum sclerostin measurements.

Authors:  Bart L Clarke; Matthew T Drake
Journal:  Bonekey Rep       Date:  2013-06-05

7.  Increased sclerostin and preadipocyte factor-1 levels in prepubertal rhythmic gymnasts: associations with bone mineral density, body composition, and adipocytokine values.

Authors:  J Jürimäe; V Tillmann; A Cicchella; C Stefanelli; K Võsoberg; A L Tamm; T Jürimäe
Journal:  Osteoporos Int       Date:  2015-09-01       Impact factor: 4.507

8.  Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.

Authors:  Z E Belaya; L Y Rozhinskaya; G A Melnichenko; A G Solodovnikov; N V Dragunova; A V Iljin; L K Dzeranova; I I Dedov
Journal:  Osteoporos Int       Date:  2013-01-29       Impact factor: 4.507

9.  Differential sclerostin and parathyroid hormone response to exercise in boys and men.

Authors:  B Falk; F Haddad; P Klentrou; W Ward; K Kish; Y Mezil; S Radom-Aizik
Journal:  Osteoporos Int       Date:  2015-09-11       Impact factor: 4.507

Review 10.  Pathogenesis of age-related bone loss in humans.

Authors:  Sundeep Khosla
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-08-24       Impact factor: 6.053

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.